Calculators and Tools for Heart Failure

NYHA classification: Class I = no symptoms with ordinary physical activity; Class II = mild symptoms (dyspnea, fatigue) with moderate exertion, comfortable at rest; Class III = symptoms with minimal exertion, comfortable only at rest; Class IV = symptoms at rest, unable to carry out any activity without discomfort. NYHA class guides treatment intensity, prognosis, and device eligibility. NYHA III–IV with LVEF <35% despite optimal medical therapy is an indication for ICD and CRT consideration. NYHA class is subjective — ACC/AHA stages (A–D) provide a parallel structural framework.

Current ACC/AHA/HFSA 2022 guidelines recommend four drug classes for HFrEF (LVEF ≤40%): (1) ACE inhibitor/ARB/ARNI (sacubitril-valsartan preferred if tolerated); (2) evidence-based beta-blocker (carvedilol, metoprolol succinate, or bisoprolol); (3) mineralocorticoid receptor antagonist (spironolactone or eplerenone); (4) SGLT2 inhibitor (dapagliflozin or empagliflozin). All four classes reduce mortality and hospitalization. SGLT2 inhibitors also benefit HFmrEF (LVEF 41–49%) and HFpEF (LVEF ≥50%) — the only class with proven benefit across all HF phenotypes.

Cardiorenal syndrome is common — declining eGFR occurs in up to 50% of acute decompensated HF admissions. Key thresholds: ACE inhibitors/ARBs — continue down to eGFR 15 with monitoring (expect up to 30% creatinine rise); spironolactone — caution at eGFR <30, avoid at eGFR <25; SGLT2 inhibitors — continue for cardiac benefit down to eGFR 20; diuretics — loop diuretics preferred over thiazides at eGFR <30. A worsening creatinine during diuresis does not always mean true renal injury — assess volume status and track trend.

AFib and heart failure frequently coexist, each worsening the other. Rate control target: resting HR <80 bpm in symptomatic patients (RACE II trial). Beta-blockers are first-line for rate control in HFrEF; digoxin can be added. Rhythm control (cardioversion, catheter ablation) may be considered — the CASTLE-AF trial showed ablation reduced mortality and HF hospitalization in HFrEF with AFib. Anticoagulation: all HF patients with AFib and CHA₂DS₂-VASc ≥2 (men) or ≥3 (women) should receive a DOAC. VKA is preferred with severe mitral stenosis or mechanical valves.

In HFrEF, the primary goal is uptitration of guideline-directed therapy — BP targets are secondary. Optimal BP is generally 110–130 mmHg SBP; lower targets (<110) may limit uptitration of life-saving medications. In HFpEF, hypertension control to <130/80 mmHg is critical as uncontrolled BP is a major driver of diastolic dysfunction. Hypotension (SBP <90 mmHg or MAP <65 mmHg) in acute decompensated HF warrants inotrope or vasopressor support and is a red flag for cardiogenic shock.

Refer to a heart failure specialist or cardiologist for: newly diagnosed HF (for echocardiogram and GDMT initiation); LVEF ≤35% (ICD/CRT evaluation); refractory symptoms despite optimal therapy; recurrent HF hospitalizations; consideration of advanced therapies (LVAD, transplant evaluation); complex comorbidities (amyloidosis, sarcoidosis, hypertrophic cardiomyopathy); or need for invasive hemodynamic assessment. Early specialist involvement improves GDMT uptitration rates and reduces mortality. NYHA Class IV despite optimal therapy should prompt advanced HF referral.